Doublet vs Triplet Bortezomib-Based Therapy for Renal Recovery in Myeloma Cast Nephropathy
For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.
Multiple Myeloma
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Novel Triple Therapy With First-in-Class Selinexor Improves Outcomes in Multiple Myeloma
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
Real-World Data Suggest Prolonged Lenalidomide Maintenance Therapy Is Beneficial in Patients With MRD-Positive Multiple Myeloma
Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Depression/Antidepressant Use Associated With QOL but not OS in Patients With Hematologic Malignancies Undergoing HSCT, Study Finds
This study separately evaluated the impact of depression/antidepressant use on the QOL and OS of cohorts of patients undergoing allogeneic or autologous HSCT.
Autologous Stem Cell Transplantation Outcomes in Multiple Myeloma vs Non-Hodgkin Lymphoma
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
Practical Guidance for Managing Selinexor-Associated Adverse Events
Involvement of nurses trained in the management of selinexor-associated AEs in patients with multiple myeloma is a key element of these recommendations.
Tocilizumab Shows Benefit in a Patient With COVID-19 and Multiple Myeloma
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
-
Loading...
-
Loading...
Next post in General Oncology
